[Cai Zhi Toutiao] Each piece is less than 8.57 yuan, the first anti -new crown oral medication is here

On August 7, Henan True Biotechnology Co., Ltd. reported that: At present, the price of Azf, which treats the new crown pneumonia, is initially set. 8.57 yuan.

On July 25, in accordance with the relevant provisions of the Drug Management Law, the State Drug Administration shall conduct emergency review and approval in accordance with the special approval procedures for the drug, and approve the conditions of Henan Real Biotechnology Co., Ltd. Azf fixed tablet. Application. This means that Azf's fixed film has become the first newly -developed oral small crown therapy drug in China.

Source: official website of the State Drug Administration

It is reported that shortly after the application of Azf's fixed setting, the real creature submitted a listing application to the Hong Kong Stock Exchange. The prospectus shows that the real creature has hired independent third -party Beijing Union production of Azfdin. For the commercialization of Azfdin, it has entered into a strategic agreement with several leading pharmaceutical manufacturers (including Beijing Union) in China. At the same time, the real creature pointed out that it has a self -production capacity of 22,262 square meters of a total construction area, with an annual production capacity of about 1 billion tablets Azfdin, and plans to seek to include Azf into the Chinese national medical insurance directory.

Clear the virus in about 5 days

It has a good effect on patients with critical condition

According to the clinical trials announced by Henan Real Biotechnology Co., Ltd. on July 15, the results of Azf's fixed crown virus pneumonia indicator registered phase III clinical trial results have reached expectations. Clinical symptoms have the effect of inhibiting the new coronary virus, and the virus clearance time is about 5 days. In terms of security, Azf's decisive chip is generally tolerated.

The Beijing Daily previously reported that more than 800 patients with clinical trials in the third phase of the third phase of the clinical trial covered the mildness, neutral and severe diseases of new crown pneumonia cases, and using virus load and clinical benefits as evaluation indicators, which is conducive to making the efficacy of the drugs to make the efficacy of the drug. Comprehensive and comprehensive evaluation.

"From the current clinical effects, this drug has very good effect on some patients with critical illness." Chang Junbiao, a professor at Henan Normal University, said that for different new crown pneumonia virus variants (Alpha, Beta, Delta, Ami, Ami Ke Rong et al.), Azf has the characteristics of very small dosage, good treatment effect, and a very fast decrease in virus.

It is worth noting that the increase in the treatment of new coronary virus pneumonia adaptation this time is "attached to the condition". In the relevant announcement, the State Drug Administration requested real creatures to continue to carry out relevant research work, complete the requirements for qualified conditions within a time limit, and submit subsequent research results in a timely manner.

The price of treatment is far lower than that of similar medicines around the world

At present, the price of Azf, which treats the new crown pneumonia, is initially determined that it is less than 300 yuan per bottle, 35 tablets per bottle, 1 mg per tablet, less than 8.75 yuan. The price of Azifidine AIDS is 25.86 yuan/mg (piece).

Not only that, Azfdin's single treatment price for new crowns is far lower than similar drugs in the world. As of the end of June this year, only two new crown small molecular drugs in the world have been approved. One is Molnupiravir and Pfizer's Nametvid. Among them, PAXLOVID was approved by the China State Drug Administration in February this year, and the purchase price in the United States was US $ 529 per treatment (about 3570 yuan). After being temporarily incorporated into medical insurance in my country, the purchase price is 2300 yuan per treatment.

Chang Junbiao, a professor at Henan Normal University, said that due to the special target and good drug activity, Azf's dosage was very small. A brokerage chief medical analyst also said that a real biological expert had previously revealed at the telephone meeting that the amount of Azfdin's new crown was 5 mg per day and a course of treatment in 7 days. Based on this, a bottle of medicine is corresponding to the new crown treatment course, the price is less than 300 yuan, which is roughly one -eighth of Paxlovid's single treatment price.

Born out of anti -Ai -antidical

my country has completely independent intellectual property rights

Azf is the first China -first self -intellectual property rights and global patented treatment of new crown pneumonia. Prior to this, Phaxlovid, who was approved by the domestic listing in February, was the only new crowned small molecule oral medication that has been listed in the domestic market.

Azf was originally a drug developed by Zhengzhou University and Henan Analysis and Test Research Center. It was successfully developed by Henan Normal University professor Chang Junbiao. This is the world's first double -target anti -AIDS innovation medicine. It has applied for patents in many countries such as China, the United States and other countries.

In July 2021, Azf's anti -AIDS indications have been approved to be listed in China. As a antivirus small molecule oral medication, Azfdin has a broad -spectrum to inhibit the replication of RNA virus, while the new coronal virus belongs to the virus of RNA as a genetic material. Therefore Essence The results of clinical III test show that while Azf is scheduled to inhibit the new coronal virus, it can significantly improve clinical symptoms and have good safety.

The concept of New Crown Medicine has risen strongly on the 8th

On August 8th, Takura Pharmaceuticals rose nearly 12%. Dali Pharmaceuticals, Xinhua Pharmaceutical's daily limit, essence pharmaceutical, Chinese medicine rose about 7%, China Resources Shuanghe, Panlong Pharmaceutical, Hongri Pharmaceutical, etc. %, Ao Xiang Pharmaceutical rose nearly 5%.

Among them, Xinhua Pharmaceutical, China Resources Shuanghe, and Aoxiang Pharmaceutical have all announced cooperation with real creatures. On April 26, Xinhua Pharmaceutical issued an announcement, becoming product manufacturers and dealers of real creature Azfding and other products in China and other countries agreed by both parties. On May 8th, China Resources Shuanghe issued an announcement and signed Azfdin's "Entrusted Processing Production Agreement" and "Strategic Cooperation Agreement" with real creatures. On May 10, Ao Xiang Pharmaceutical issued an announcement that its wholly -owned subsidiary signed the "Entrusted Processing Production Framework Agreement" with real creatures. On July 25, Fosun Pharmaceutical also issued an announcement, and the holding subsidiary signed the "Strategic Cooperation Agreement" with the real creature.

In addition to Azf's approved, domestic oral drugs with a faster progress include the VV116 of Junshi Bio, SIM0417 of Puklunamide and Pioneer Pharmaceuticals in Pharmaceuticals. In addition New crown drugs of oral small molecules of many companies are at different research stages.

New crown oral administration drugs have become new tracks in pharmaceutical companies

Under the global epidemic of new coronary pneumonia, "vaccine+special effects medicine" is considered the best combination of prevention and treatment. At present, the new crown vaccine has achieved great success and play a huge role in the world, and the new crown oral medicine needs to accelerate the "epidemic" of the operation. With the spread of Omikon and its mutant strains, the treatment of new crown oral treatment drugs has become a new track chasing domestic and foreign pharmaceutical companies.

Among them, small molecular drugs are highly hoped for their unique mechanisms and oral convenience. In foreign countries, Molnupiravir and Phard's Paxlovid of Merck have taken the lead in listing.

According to Beijing Daily, oral small molecules New Crown Drugs focus on the effect of eliminating the virus by interfering with the replication of the new crown virus itself, low sensitivity to virus mutation, and do not need medical staff and other professionals. It is an effective means to control the spread of the epidemic. However, small molecular drugs have the phenomenon of "Fuyang". It may be very effective after taking it for five days, and the symptoms are reduced, but the symptoms will be repeated in about ten days. Recently, overseas media disclosed that Paxlovid developed by Pfizer was also reported by many new -crowned patients.

(WeChat public account "Caizhi Headline" comprehensive self: Securities Times, Daily Economic News, Shangguan News, Financial Association, etc.)

Edit: Yuan Kai

School pair: Fenghua

Review: Gong Zimo

- END -